Sanofi disclosed its fourth‑quarter and full‑year 2025 financial results on January 29 2026, reporting a headline earnings‑per‑share (EPS) of €1.53 that surpassed the consensus estimate of €0.84 by €0.69, a 82 % surprise. Revenue for the quarter reached €11.3 billion, falling short of the €13.58 billion consensus by €2.28 billion, or 16.8 % below expectations.
Revenue growth was driven by a 30 % increase in patient numbers for Dupixent, which generated €15.7 billion in full‑year sales, and by the launch of new pharmaceutical products such as Ayvakit and ALTUVIIIO. However, the vaccines segment posted a 2.5 % decline, and overall sales volume pressure in the legacy product portfolio contributed to the revenue miss. Compared with Q4 2024, revenue rose from €10.56 billion to €11.3 billion, a 7.2 % year‑over‑year increase that still fell short of analyst forecasts.
The EPS beat was largely a result of disciplined cost management and a favorable product mix. Gross margin expanded by 1.8 percentage points to 77.5 %, driven by higher specialty‑medicine sales and lower generic‑drug volumes. Operating income grew to €2.1 billion from €1.9 billion, reflecting the margin lift and efficient allocation of research and development spend. The combination of higher margins and controlled operating expenses enabled Sanofi to deliver a robust EPS surprise despite the revenue shortfall.
For 2026, Sanofi guided for high single‑digit sales growth and projected business EPS to grow slightly faster than sales, signaling confidence in continued profitability. The company also reaffirmed its strategic shift toward an R&D‑driven, AI‑powered biopharma model, emphasizing investment in next‑generation therapies and data‑driven drug discovery. Management highlighted the importance of the upcoming Dynavax acquisition, expected to close in Q1 2026, and the completion of the Vicebio deal, both of which are expected to broaden the company’s vaccine and biologics pipeline.
CEO Paul Hudson noted that the EPS beat reflected “strong execution on cost control and a favorable product mix” and reiterated the company’s commitment to delivering long‑term shareholder value through a €1 billion share‑buyback program for 2026, following a €5 billion buyback completed in 2025. The market reacted positively, with Sanofi’s shares rising 1.25 % in pre‑market trading, largely driven by the EPS surprise and the company’s optimistic outlook.
The earnings release underscores Sanofi’s resilience in a competitive specialty‑medicine landscape and highlights the company’s strategic focus on high‑margin products and AI‑enabled research, positioning it for sustained growth in the coming years.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.